DEFA14A: Masimo Defends Leadership Amidst Proxy Fight with Politan Capital

Masimo updates its website to advocate for its current leadership and highlight its achievements amidst a proxy battle with Politan Capital Management.

Summary

• Masimo has updated its website, www.ProtectMasimosFuture.com, to provide information related to its 2024 Annual Meeting of Stockholders.
• The updates include testimonials from individuals like Dr. Najemdin Meshkati, who emphasizes Masimo's role in patient safety and the importance of reducing medical errors.
• The website also features a news article discussing the influence of proxy advisors like ISS and Glass Lewis, suggesting they may be swayed by agendas not aligned with shareholder value.
• CEO Joe Kiani addresses shareholders, highlighting the company's mission, past achievements, and plans for board declassification and expansion.
• Kiani accuses Politan and Mr. Koffey of sabotaging the company and spreading lies.
• Independent director nominee Chris Chavez emphasizes his independence and experience in the med-tech industry, advocating for the current leadership.
• Independent director Bob Chapek expresses confidence in Joe Kiani's leadership and the company's strategy.
• Masimo includes forward-looking statements regarding the 2024 Annual Meeting and potential risks and uncertainties.
• The company urges stockholders to read the Amended Revised Proxy Statement for important information.
• The document also includes advertisements by Masimo appearing on several websites, beginning on September 13, 2024.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive, focusing on Masimo's achievements and future potential, but tempered by the ongoing proxy fight and accusations against Politan.

Positives

• Masimo has a strong history of innovation and a clear mission to improve patient outcomes.
• The company has a large patent portfolio, with over 900 patents held by CEO Joe Kiani.
• Masimo is taking steps to address shareholder concerns, such as declassifying the board and increasing its size.
• The company has a strong and positive corporate culture.
• Masimo has a clear strategy to position the business for the future and drive value creation.

Negatives

• Masimo is facing a proxy fight with Politan Capital Management, which is causing management distraction and uncertainty.
• CEO Joe Kiani accuses Politan of sabotaging the company and spreading lies.
• The company's stock has stagnated over the last few years.
• Masimo is facing uncertainties regarding litigation.

Risks

• The outcome of the proxy fight with Politan Capital Management is uncertain.
• Potential management distraction and costs associated with the proxy fight.
• Litigation risks.
• Uncertainties regarding future actions that may be taken by Politan.
• The influence of proxy advisors like ISS and Glass Lewis could impact the shareholder vote.

Future Outlook

Masimo aims to continue improving patient outcomes, reducing the cost of care, and growing its business as a public company. The company plans to increase its board size and declassify the board. The company is executing a clear strategy to position the business for the future and drive value creation.

Management Comments

• Joe Kiani: 'Weve been listening to our shareholders. Weve been asking them what they want.'
• Joe Kiani: 'There is so much at stake here that I ask you to please read the complaints, read what were sending you.'
• Chris Chavez: 'I understand the respective role of management and of an independent board and how they should interact for the benefit of shareholders, customers and employees.'
• Bob Chapek: 'I am confident that Joes unique vision for the company, combined with the support of the right directors, myself included, represents the path forward for all stakeholders.'

Industry Context

The document highlights the increasing influence of proxy advisory firms like ISS and Glass Lewis in corporate governance, particularly in the context of ESG investing. It also touches on the trend of companies choosing to remain private due to the high costs and inflexibility of being a public company.

Comparison to Industry Standards

• The document references Apple and Masimo's legal battle over pulse-oximetry technology, highlighting Masimo's innovation in the medical technology space.
• The article mentions that Bank of America estimates compliance costs incurred solely to be a public company are $8-11.5 million per year.
• The document references JP Morgan CEO Jamie Dimon's 2024 annual letter, highlighting the problem of the consultification of finance.
• The document mentions that in 1996, the U.S. boasted 7,300 publicly traded firms, but today that number is just around 4,300.

Corporate Governance

Legal Proceedings

• Masimo has filed a complaint against Politan and Mr. Koffey.
• The document references Masimo's legal battle with Apple over pulse-oximetry technology.

Stakeholder Impact

• The outcome of the proxy fight could impact shareholders, employees, and customers.
• The company's strategy and leadership will affect its ability to deliver value to stakeholders.
• The company's focus on patient safety and innovation benefits patients and the healthcare industry.

Next Steps

• Shareholders need to vote on the director nominees at the 2024 Annual Meeting.
• Masimo will continue to engage with shareholders and address their concerns.
• The company will continue to execute its strategy to drive value creation.

Key Dates

Keywords

Masimo, Politan, Proxy Fight, Joe Kiani, Shareholders, Board of Directors, Corporate Governance, Patient Safety, Medical Technology, ISS, Glass Lewis